



ORIGINAL ARTICLE

## Dual antiplatelet therapy in myocardial infarction with non-obstructive coronary artery disease – insights from a nationwide registry



Fernando Montenegro Sá<sup>a,\*</sup>, Rita Carvalho<sup>a</sup>, Luís Santos<sup>a</sup>, Catarina Ruivo<sup>a</sup>, Alexandre Antunes<sup>a</sup>, Adriana Belo<sup>b</sup>, Francisco Soares<sup>a</sup>, João Morais<sup>a</sup>, on behalf of the Portuguese Registry of Acute Coronary Syndromes

<sup>a</sup> Cardiology Department, Centro Hospitalar de Leiria, Leiria, Portugal

<sup>b</sup> Portuguese Society of Cardiology, Lisboa, Portugal

Received 5 September 2019; accepted 5 May 2020

### KEYWORDS

Acute coronary syndrome;  
Myocardial infarction;  
Dual antithrombotic therapy

### Abstract

**Introduction and objectives:** Dual antiplatelet therapy (DAPT) is a mainstay for myocardial infarction (MI) therapy. However, in patients with myocardial infarction with non-obstructive coronary artery disease (MINOCA), clear recommendations are lacking in the literature. This study aims to identify the cases in which DAPT is currently prescribed at discharge for MINOCA. **Methods:** The authors analyzed a cohort of patients from a multicenter national registry enrolling patients who suffered their first MI between 2010 and 2017, and underwent coronary angiography revealing absence of stenosis  $\geq 50\%$ . Individual antithrombotic therapy was identified. A logistic regression analysis was applied to search for predictors of DAPT.

**Results:** From a total of 16 237 patients analyzed, 709 (4.4%) were categorized as MINOCA. Mean age was  $64 \pm 13$  years, 46.3% (n=409) were females. 390 (55.0%) of MINOCA patients were discharged on DAPT. Males (OR 1.67, CI 95 [1.05-2.38],  $p=0.027$ ), active smokers (OR=1.82, CI 95 [1.05-3.16],  $p=0.033$ ), previous percutaneous intervention (OR 3.18, CI 95 [1.48-6.81],  $p=0.003$ ), ST elevation MI (OR 2.70, CI 95 [1.59-4.76],  $p<0.001$ ) and sinus rhythm at admission (OR=3.94, CI 95 [2.07-7.48],  $p<0.001$ ) were independent predictors of DAPT use.

**Conclusion:** In this nationwide registry, DAPT was prescribed at discharge in 55% of MINOCA patients. Beyond sinus rhythm, the variables presented as independent predictors for DAPT use identify subgroups of patients who are classified as more prone to thrombotic events. The issue of how to handle antithrombotic agents in MINOCA patients is a topic open for discussion.

© 2020 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author.

E-mail address: [fernando.m.sa@gmail.com](mailto:fernando.m.sa@gmail.com) (F. Montenegro Sá).

**PALAVRAS-CHAVE**

Síndrome coronária aguda;  
 Enfarte agudo do miocárdio;  
 Dupla terapêutica antiplaquetária

## Dupla antiagregação plaquetar em doentes com enfarte agudo do miocárdio sem doença coronária obstrutiva – dados de um registo nacional

**Resumo**

*Introdução e objetivos:* A dupla antiagregação plaquetar (DAPT) assume um papel central no tratamento dos doentes com enfarte agudo do miocárdio (EAM). Não há, no entanto, indicações claras para o tratamento de doentes com EAM sem doença coronária obstrutiva (MINOCA). Este artigo tem por objetivo identificar em que doentes com MINOCA é atualmente prescrita DAPT. *Métodos:* Os autores analisaram uma coorte de doentes de um registo nacional multicêntrico incluindo doentes com um primeiro EAM entre 2010 e 2017 e que realizaram coronariografia que revelasse ausência de qualquer estenose  $\geq 50\%$ . A terapêutica antitrombótica individualizada foi identificada e, de forma a determinar preditores da utilização de DAPT, uma regressão logística foi aplicada.

*Resultados:* De 16 237 doentes, 709 (4,4%) foram classificados como MINOCA. A idade média foi  $64 \pm 13$  anos, 46,3% do género feminino. Dos doentes com MINOCA 390 (55,0%) tiveram alta hospitalar sob DAPT. O género masculino (OR 1,67, 95CI [1,05-2,38],  $p=0,027$ ), ser fumador ativo (OR=1,82, 95CI [1,05-3,16],  $p=0,033$ ), ter pelo menos uma intervenção coronária percutânea prévia (OR 3,18, 95CI [1,48-6,81],  $p=0,003$ ), o diagnóstico de EAM com supradesnivelamento do segmento ST (OR 2,70, 95CI [1,59-4,76],  $p<0,001$ ) e a presença de ritmo sinusal à admissão (OR=3,94, 95CI [2,07-7,48],  $p<0,001$ ) foram os preditores independentes para a utilização de DAPT.

*Conclusão:* Neste estudo baseado num registo nacional, DAPT foi prescrita à alta a 55% dos doentes com MINOCA. Para além da presença de ritmo sinusal, os preditores independentes de utilização de DAPT identificam um subgrupo de doentes habitualmente classificado como tendo maior risco de eventos tromboticos. A questão de como lidar com o esquema antitrombótico de doentes com MINOCA permanece um tópico em discussão.

© 2020 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Introduction**

Dual antiplatelet therapy (DAPT) is one of the mainstays of medical management in patients with acute coronary syndrome (ACS).<sup>1,2</sup> However, when a myocardial infarction (MI) occurs in the absence of obstructive coronary artery disease (CAD), the role of DAPT is not established. In 2017, the first authoritative international expert opinion was published by the European Society of Cardiology (ESC), defining myocardial infarction with non-obstructed coronary artery (MINOCA) as a working diagnosis – an MI in the absence of obstructive CAD on angiography in any potential infarct-related artery (no coronary artery stenosis  $\geq 50\%$ ), and no clinically overt specific cause for the acute presentation.<sup>3</sup> Our group has already published the first trial studying Portuguese MINOCA patients, identifying a mortality rate of nearly 9% in a three-year follow-up of our single-experience.<sup>4</sup> Recently, the ESC included a chapter dedicated to MINOCA patients in the 2017 guidelines for the management of acute MI in patients presenting with ST-segment elevation<sup>1</sup> as well as in the fourth universal definition of MI.<sup>5</sup> It is highlighted that this is a working diagnosis requiring specific investigation and treatment. However, there are still no clear treatment guidelines, and the ESC states that more research into this topic is required. The only trial to date addressing this issue reported a neutral benefit for DAPT,<sup>6</sup> and the first randomized controlled trial is

currently in development (the MINOCA-BAT trial, ClinicalTrials.gov identifier NCT03686696). Thus, the present study aims to answer the following question: In which MINOCA patients do clinicians currently believe that DAPT can be useful?

**Methods**

The Portuguese Registry of Acute Coronary Syndromes (ProACS) is an observational nationwide multicenter registry enrolling adult patients (>18 years) with an episode of ACS (ClinicalTrials.gov identifier NCT01642329).<sup>7,8</sup> According to the current universal definition of MI, only type 1 MI patients are eligible.<sup>5</sup> Demographic data, medical history, presenting symptoms, biochemical, electro and echocardiography data, pharmacological therapies, invasive procedures, in-hospital complications and mortality are collected using a standardized data collection form. The National Ethics Committee for Clinical Research, the institutional ethics committee and review board of each center approved individual participation in the registry.

The authors analyzed the ProACS database for patients with a first MI enrolled between 2010 and 2017, including only patients who underwent a coronary angiography revealing absence of any lesion causing  $\geq 50\%$  luminal reduction. The primary endpoint was DAPT prescription at discharge. Valvular heart disease was defined according to current

**Table 1** Baseline characteristics.

	MINOCA (n=709)
Female (n, %)	328 (46.3)
Mean age (years, $\mu\pm$ CI)	64 $\pm$ 13
Body-mass index (kg/m <sup>2</sup> , $\mu\pm$ CI)	27.3 $\pm$ 4.6
Diabetes mellitus type 2 (n, %)	138 (19.5)
Active smokers (n, %)	169 (23.8)
Arterial hypertension (n, %)	460 (64.9)
Dyslipidemia (n, %)	374 (52.8)
Family history of CAD (n, %)	36 (5.1)
Previous major bleeding (n, %)	15 (2.1)
CRUSADE bleeding risk score ( $\mu\pm$ CI)	25.5 $\pm$ 15.4
Previous stable angina (n, %)	115 (16.2)
Previous PCI (n, %)	72 (10.2)
Chronic kidney disease (n, %)	26 (3.7)
Previous medication: Aspirin (n, %)	177 (25.1)
Previous medication: Clopidogrel (n, %)	78 (11.0)
Previous medication: ACEi/ARB (n, %)	301 (42.9)
Previous medication: BB (n, %)	156 (22.2)
Previous medication: Statins (n, %)	245 (34.8)
Diagnosis: ST-segment elevation myocardial infarction (n, %)	108 (15.2)
Killip Kimball class>I (n, %)	77 (10.9)
Sinus rhythm (n, %)	613 (86.5)
Trivial coronary lesions: <50% stenosis (n, %)	256 (36.1)

ACEi: angiotensin converter enzyme inhibitors; ARB: angiotensin receptor blocker; BB: beta blockers; CAD: coronary artery disease; CI: confidence interval; MINOCA: myocardial infarction with non-obstructive coronary artery disease; PCI: percutaneous coronary intervention.

guidelines,<sup>9</sup> and included in the analysis if it presented at least moderate severity. The definitions of registry variables have already been published in the literature.<sup>7,8</sup> Regarding statistical analysis, categorical variables are presented as frequency values and continuous variables are presented as mean ( $\mu$ )  $\pm$  standard deviation. Due to sample size, normal distribution of variables was assumed and parametric tests were used for between-group comparison. Comparisons between groups were made for each included variable with a known result, by using a chi-square test or a Student's t-test when appropriate. Statistical significance was defined as a p-value <0.05. To better represent the antiplatelet strategy of the attending cardiologists, data regarding the use of DAPT in-hospital and at discharge were also compared. In order to determine the independent predictors for DAPT use at discharge, a multivariate logistic regression analysis with stepwise-forward method was performed for each group, including all pharmacological treatment and also pre-hospital, clinical and laboratorial data, ACS classification and coronary anatomy. Model calibration was assessed with the Hosmer-Lemeshow test.

## Results

Of the 16 237 patients included in the registry, 709 (4.4%) were classified as MINOCA. Clinical baseline characteristics are described in [Table 1](#).

At discharge, DAPT was prescribed to 55.0% (n=390) of patients. Univariate comparison of both DAPT and non-DAPT groups is presented in [Table 2](#).

DAPT group patients were older (66 $\pm$ 13 vs. 63 $\pm$ 13, p=0.013), had fewer female patients (39.2% vs. 54.9%, p<0.001) and more active smokers (30.3% vs. 16.0%, p<0.001). Previous percutaneous coronary intervention (PCI), 14.9% vs. 4.4%, p<0.001), aspirin (28.5% vs. 20.7%, p=0.018) or clopidogrel (13.3% vs. 8.2%, p=0.029) were more prevalent in the DAPT group. At admission, patients discharged on DAPT had higher ST elevation MI diagnosis (STEMI) (19.7% vs. 9.7%, p<0.001), sinus rhythm (92.5% vs. 79.3%, p<0.001) and trivial coronary lesions on coronary angiography (50.8% vs. 18.2%, p<0.001). The presence of at least moderate valvular heart disease was more frequent in the non-DAPT group (5.7% vs. 1.8%, p=0.006). In a univariate comparison, the baseline CRUSADE bleeding risk score was higher in the MINOCA patients that were discharged without DAPT (27.0 $\pm$ 15.2 vs. 24.1 $\pm$ 15.4 p=0.015).

A comparison of the in-hospital and at discharge antiplatelet strategy between STEMI and non-STEMI patients is presented in [Table 3](#); in both situations, there was a higher prevalence of DAPT prescription in STEMI patients.

After multivariate analysis, independent predictors of DAPT use were identified ([Table 4](#)). The Hosmer-Lemeshow test showed good calibration for this model (p=0.998).

## Discussion

In this nationwide trial which included 709 MINOCA patients, DAPT was prescribed at discharge to 55.0% (n=390) of subjects. This is the first trial specifically studying the Portuguese prescription pattern in MINOCA patients and one of the largest currently published trials regarding MINOCA. A trial by Paolisso et al., which included 134 MINOCA patients, identified a 42.1% rate for DAPT prescription at discharge,<sup>10</sup> while analysis by the SWEDEHEART registry indicates a 66.4% rate of DAPT prescription at discharge.<sup>6</sup> Our results thus corroborate previously published data. The explanation for this rate of DAPT in patients with non-obstructive CAD is, however, not clear. As a working diagnosis, MINOCA represents a heterogeneous group of patients,<sup>11</sup> making specific therapy difficult. Underlying etiologies include some clinical scenarios in which any degree of antithrombotic treatment could be recommended (such as plaque erosion, coronary embolism, missed ostial coronary occlusion, coronary artery dissection, pulmonary embolism or thrombophilia),<sup>3,12</sup> but other causes may also be present (myocarditis, Takotsubo cardiomyopathy, and cardiac trauma, for example).<sup>3,13</sup> In our trial, we believe that since the ProACS registry does not include patients in whom myocarditis or Takotsubo cardiomyopathy is the first suspected diagnosis, its prevalence as the underlying etiology may be lower than in other trials.<sup>4,13,14</sup> Hence, the remaining MINOCA causes may include a proportionally higher rate of situations for which DAPT is thought to have a beneficial impact. Overall, and according to the baseline data presented ([Tables 1 and 2](#)), few MINOCA patients had a previous major bleeding event (n=15, 2.1%). Despite the CRUSADE bleeding risk score being lower in patients that were discharged under DAPT, both values represent a low risk status (corresponding to a mean

**Table 2** Univariate comparison by study group.

	DAPT (n=390)	No-DAPT (n=319)	p-value
Female (n, %)	153 (39.2)	175 (54.9)	<0.001
Age (years, $\mu\pm$ CI)	66 $\pm$ 13	63 $\pm$ 13	0.013
BMI (kg/m <sup>2</sup> , $\mu\pm$ CI)	27.6 $\pm$ 4.3	26.9 $\pm$ 4.6	0.051
Type 2 diabetes (n, %)	83 (21.3)	55 (17.2)	0.183
Active smokers (n, %)	118 (30.3)	51 (16.0)	<0.001
Hypertension (n, %)	251 (65.0)	209 (67.0)	0.587
Dyslipidemia (n, %)	202 (54.3%)	172 (56.2)	0.619
Family history of CAD (n, %)	19 (5.4)	17 (5.8)	0.794
Previous stable angina (n, %)	55 (14.1)	60 (18.9)	0.087
Previous PCI (n, %)	58 (14.9)	14 (4.4)	<0.001
Previous $\geq$ moderate valvular disease (n, %)	7 (1.8)	18 (5.7)	0.006
Chronic kidney disease (n, %)	9 (2.3)	17 (5.3)	0.035
Previous major bleed (n, %)	5 (1.3)	10 (3.3)	0.085
CRUSADE bleeding risk score ( $\mu\pm$ CI)	24.1 $\pm$ 15.4	27.0 $\pm$ 15.2	0.015
Previous medication: Aspirin (n, %)	111 (28.5)	66 (20.7)	0.018
Previous medication: Clopidogrel (n, %)	52 (1.3)	26 (8.2)	0.029
Previous medication: ACEi/ARB (n, %)	168 (43.1)	133 (41.7)	0.702
Previous medication: BB (n, %)	89 (22.8)	67 (21.0)	0.557
Previous medication: Statins (n, %)	139 (35.6)	106 (33.2)	0.508
STEMI diagnosis (n, %)	85 (21.8)	23 (7.2)	<0.001
Killip Kimball class>I	43 (11.1)	34 (10.7)	0.866
Sinus rhythm (n, %)	360 (92.5)	253 (79.3)	<0.001
Trivial coronary lesions: <50% stenosis (n, %)	198 (50.8)	58 (18.2)	<0.001

ACEi: angiotensin converter enzyme inhibitors; ARB: angiotensin receptor blocker; BB: beta blockers; BMI: body mass index; CAD: coronary artery disease; CI: confidence level; DAPT: dual antiplatelet therapy; PCI: percutaneous coronary intervention; STEMI: ST elevated myocardial infarction.

**Table 3** Antiplatelet strategy according to type of myocardial infarction.

	NSTEMI (n=601)	STEMI (n=108)	p-value
In-hospital single antiplatelet therapy (n, %)	127 (21.1)	12 (11.1)	0.015
In-hospital DAPT (n, %)	473 (78.7)	96 (88.9)	
At discharge: single antiplatelet therapy (n, %)	223 (37.1)	23 (21.3)	0.001
At discharge: DAPT (n, %)	377 (62.7)	85 (78.7)	

DAPT: dual antiplatelet therapy; NSTEMI: non-ST elevated myocardial infarction; STEMI: ST elevated myocardial infarction.

**Table 4** Multivariate analysis for DAPT independent use predictors.

	OR	95CI	p-value
Male gender	1.67	1.05-2.38	0.027
Active smoker	1.82	1.05-3.16	0.033
Previous PCI	3.18	1.48-6.81	0.003
Diagnosis: ST-segment elevation myocardial infarction	2.70	1.59-4.76	<0.001
Sinus Rhythm at admission	3.94	2.07-7.48	<0.001

DAPT: dual antiplatelet therapy; PCI: percutaneous coronary intervention.

bleeding risk score  $\leq$ 5%).<sup>15,16</sup> Also, after multivariate analysis, bleeding risk was not an independent predictor of DAPT use. Beyond sinus rhythm, the other variables presented as independent predictors identify groups of patients who are usually thought of as more prone to thrombus formation and pro-thrombotic events. There was a higher prevalence of DAPT prescription both in-hospital and at discharge in

STEMI patients which has already been described in patients with obstructive CAD.<sup>17</sup> Non-sinus rhythm patients include those who clearly benefit from anticoagulation,<sup>18</sup> and DAPT use would increase their bleeding risk significantly.<sup>18</sup> Studies of intracoronary imaging have shown that nearly 40% of patients with MINOCA have some evidence of plaque disruption,<sup>19</sup> where DAPT may be useful.<sup>20</sup> A recent study

using optical coherence tomography and cardiac magnetic resonance (CMR) in 38 consecutive MINOCA patients identified plaque disruption in 24% and thrombus in 18% of the studied coronary arteries, in a total of 11 (28.9%) patients.<sup>21</sup>

This analysis of the ProACS registry, which included more than 17 000 patients, indicated a 4.4% prevalence of MINOCA. There is a substantial variability in reported prevalence of MINOCA, according to definitions applied and to the baseline population studied, with a range of 3.5 to 15%.<sup>3,4,10,12,13,22</sup> Hence, the prevalence presented herein is in-line with the previously published data, with the exception of a predominance of male subjects. With regard to baseline characteristics, our population presents a similar prevalence of cardiovascular risk factors to other MINOCA populations described in the literature.<sup>4,23</sup> STEMI was diagnosed in 15.2% of patients, similar to the data presented in the SWEDEHEART registry analysis (17%).<sup>6</sup>

Regarding limitations, the final etiological diagnosis was not considered in the ProACS registry. One particular concern is about the unknown use of CMR to reach a final diagnosis.<sup>24</sup> However, our aim was to identify in which MINOCA patients DAPT is currently used, in both undiagnosed and during diagnostic work-up patients – where CMR is essential. In fact, recent authors have recommended the exclusion of myocarditis before establishing a MINOCA diagnosis work-up, since it is a highly frequent cause of chest pain and troponin elevation without CAD and has an established therapeutic approach and known prognosis.<sup>4,25</sup> However, as previously mentioned, the ProACS registry excludes all patients in whom myocarditis is the main suspected diagnosis, limiting the impact of this factor in our analysis. Other limitations include the fact that coronary angiography was not routinely reviewed to search for missing stenosis or coronary artery dissection. Data obtained from intracoronary imaging studies is not available in the ProACS registry. The addition of intravascular imaging could provide interesting data regarding other diagnoses, especially non-obstructive plaque thrombosis and coronary artery dissection, as previous trials have proven.<sup>22,26</sup> Finally, at the time of this analysis, no follow-up data was available for these patients, therefore, it was not possible to assess the incidence of bleeding according to the antithrombotic therapy used. The ProACS registry does not include all Portuguese centers managing patients with ACS, thus national prevalence of MINOCA may be underrepresented. Even when appropriately diagnosed, the management of MINOCA patients will vary depending on local practices and hospital resources.<sup>14</sup> However, few nationwide registries have higher levels of representativeness:<sup>27</sup> the ProACS registry is currently only surpassed by the SWEDEHEART and the MINAP registries,<sup>28,29</sup> and the SWEDEHEART registry presents a published MINOCA rate of 8%.<sup>6</sup>

Since DAPT had a neutral effect in the only single trial to date addressing secondary MINOCA prevention,<sup>6</sup> the results herein presented highlight the need to perform a thorough etiological study in all MINOCA patients. The authors believe that the group of MINOCA patients discharged on DAPT represent those in whom clinicians currently believe DAPT should be of benefit, either during the time needed to achieve a final underlying diagnosis or in those in whom a final diagnosis is never achieved. Future trials on MINOCA therapy (such as the MINOCA-BAT, ClinicalTrials.gov

identifier 03686696) will be helpful to understand which therapeutic measures we should follow for these patients.

## Conclusion

The results of this nationwide registry analysis indicate that 4.4% of patients with a diagnosis of MI had no significant CAD and that the majority (55%) of these patients were discharged on DAPT. Male patients, active smokers, the presence of sinus rhythm at admission, a STEMI diagnosis and a previous history of PCI were independent predictors of DAPT use. The issue of how to handle antithrombotic agents in MINOCA patients is a topic open for discussion and requires additional investigation.

## Conflicts of interest

The authors have no conflicts of interest to declare.

## References

1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2017.
2. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2016;37:267–315.
3. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. *Eur Heart J*. 2017;38:143–53.
4. Montenegro Sá F, Ruivo C, Santos LG, et al. Myocardial infarction with nonobstructive coronary arteries: a single-center retrospective study. *Coron Artery Dis*. 2018;29:511–5.
5. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J*. 2018.
6. Lindahl B, Baron T, Erlinge D, et al. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease. *Circulation*. 2017;135:1481–9.
7. Santos JF, Aguiar C, Gavina C, et al. Portuguese Registry of Acute Coronary Syndromes: seven years of activity. *Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia=Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology*. 2009;28:1465–500.
8. Ferreira J, Monteiro P, Mimoso J. National Registry of Acute Coronary Syndromes: results of the hospital phase in 2002. *Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia=Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology*. 2004;23:1251–72.
9. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38:2739–91.
10. Paolisso P, Bergamaschi L, Satri G, et al. Secondary prevention medical therapy and outcomes in patients with myocardial infarction with non-obstructive coronary artery disease. *Front Pharmacol*. 2019;10:1606.

11. Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. *Eur Heart J*. 2015;36:475–81.
12. Pasupathy S, Air T, Dreyer RP, et al. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. *Circulation*. 2015;131:861–70.
13. Safdar B, Spatz ES, Dreyer RP, et al. Presentation, clinical profile, and prognosis of young patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): results from the VIRGO study. *J Am Heart Assoc*. 2018;7.
14. Tamis-Holland JE, Jneid H. Myocardial infarction with nonobstructive coronary arteries (MINOCA): it's time to face reality! *J Am Heart Assoc*. 2018;7:e009635.
15. Abu-Assi E, Raposeiras-Roubin S, Lear P, et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care*. 2012;1:222–31.
16. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. *Circulation*. 2009;119:1873–82.
17. Déry JP, Mehta SR, Fisher HN, et al. Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). *Am Heart J*. 2016;181:26–34.
18. Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). *Europace*. 2018.
19. Reynolds HR, Srichai MB, Iqbal SN, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. *Circulation*. 2011;124:1414–25.
20. Xie Y, Mintz GS, Yang J, et al. Clinical outcome of nonculprit plaque ruptures in patients with acute coronary syndrome in the PROSPECT study. *JACC: Cardiovasc Imaging*. 2014;7:397–405.
21. Opolski MP, Spiewak M, Marczak M, et al. Mechanisms of myocardial infarction in patients with nonobstructive coronary artery disease: results from the optical coherence tomography study. *JACC: Cardiovasc Imaging*. 2018.
22. Vidal-Perez R, Abou Jokh Casas C, Agra-Bermejo RM, et al. Myocardial infarction with non-obstructive coronary arteries: a comprehensive review and future research directions. *World J Cardiol*. 2019;11:305–15.
23. Kilic S, Aydin G, Çoner A, et al. Prevalence and clinical profile of patients with myocardial infarction with non-obstructive coronary arteries in Turkey (MINOCA-TR): a national multi-center, observational study. *Anatolian J Cardiol*. 2020;23:176–82.
24. Sivakumar R, Amancharla RKG, Murthy SB. ACS like presentation with normal coronaries: Are they all MINOCA? Utility of cardiac MRI. *IHJ Cardiovasc Case Rep (CVCR)*. 2017;1:132–4.
25. Pasupathy S, Beltrame JF. Refining the diagnosis of myocardial infarction with nonobstructive coronary arteries. *Coron Artery Dis*. 2018;29:528–9.
26. Iqbal SN, Feit F, Mancini GB, et al. Characteristics of plaque disruption by intravascular ultrasound in women presenting with myocardial infarction without obstructive coronary artery disease. *Am Heart J*. 2014;167:715–22.
27. Timóteo AT, Mimoso J. Portuguese Registry of Acute Coronary Syndromes (ProACS): 15 years of a continuous and prospective registry. *Rev Port Cardiol (English Ed)*. 2018;37:563–73.
28. Lawesson SS, Alfredsson J, Fredrikson M, et al. Time trends in STEMI—improved treatment and outcome but still a gender gap: a prospective observational cohort study from the SWEDEHEART register. *BMJ Open*. 2012;2.
29. Herrett E, Smeeth L, Walker L, et al. The Myocardial Ischaemia National Audit Project (MINAP). *Heart (Br Cardiac Soc)*. 2010;96:1264–7.